louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07017985: Prevalence of Diabetes in Patients Who Are Candidates for Spine Surgery
Official title: Prevalence of Diabetes in Patients Who Are Candidates for Spine Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Spine Disease
Keywords: Spine surgery
Diabetes
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population of patients who are candidates for lumbar spine surgery

Brief summary: The purpose of the study is to assess, through systematic screening, the prevalence of diabetes or prediabetes in patients who are candidates for lumbar spine surgery.

Detailed description: This is a prospective, longitudinal, single-center, open-label observational study on a population of patients undergoing lumbar spine surgery.

This study does not alter patient management or the physician-patient relationship. Assessments take place during routinely scheduled consultations. Fasting blood glucose and glycated hemoglobin measurements are part of the standard preoperative assessment. Patient self-administered questionnaires are routinely completed for practice evaluation purposes and constitute a database for routine care.

Eligibility criteria: Inclusion Criteria:

* Adult patients,
* Patients who have been informed of the research and have not indicated their opposition to the use of their medical data,
* Patients who are candidates for their first lumbar spine surgery, whether instrumented or not

Exclusion Criteria:

* Non-instrumented percutaneous surgery (cementoplasty)
* Presence of spinal osteosynthesis equipment
* Surgery performed for an infectious or tumoral spinal condition
* Surgery via an anterior or lateral approach

Primary outcomes:
measure: Diabetes or prediabetes présence
timeFrame: Day 1
Secondary outcomes:
measure: Low back pain
timeFrame: Day 0
measure: Low back pain
timeFrame: Month 3
measure: Radicular pain
timeFrame: Day 0
measure: Radicular pain
timeFrame: Month 3
measure: Functional Impact of the Disease
timeFrame: Day 0
measure: Functional Impact of the Disease
timeFrame: Month 3
Other outcomes:
Locations:
city: Massy
country: France
facility: Hôpital Privé Jacques Cartier
Study officials:
References:
Clinical trial NCT00989885: ESS as a Diagnosis Resource Aid of the Syndrome of Obstructive Sleep Apnea
Official title: The Effectiveness of the Epworth´s Sleepiness Scale as a Resource Aid in the Diagnosis of the Syndrome of Obstructive Sleep Apnea
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea
Mixed Central and Obstructive Sleep Apnea
Sleep-Disordered Breathing
Keywords: Evaluation
Obstructive sleep apnea
Polysomnography
Lead sponsor: Fortaleza University
Sponsor class: OTHER
Collaborators: name: CESF - Centro de Estudos do Sono de Fortaleza LTDA
First posted: 2009-10-06
Enrollment: 475
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that sought the CESF to probable diagnosis of some sleep disorder

Brief summary: The aim of this study was to analyze the effectiveness of the Epworth's sleepiness scale as a recourse aid in the diagnosis of the syndrome of obstructive sleep apnea. 475 patients attended this study, that sought the CESF to probable diagnosis of some sleep disorder. The data were collected from records, wich are of questionnaires, including the ESE, prepared by the CESF professionals and responded, previously, by the own patients. The study compared the result obtained in the scale of Epworth with the data of polysomnography. The analysis of data was performed using the SPSS, based on descriptive and inferential statistics, being used the average considering the standard deviation, and, to the crossing of variables, was used the chi-square test of Pearson, considering as significant statistically values of p\<0.05. The results showed that gender, age and BMI are predisposing factors to SOSA.


Eligibility criteria: Inclusion Criteria:

* Charts of whose admission of patients was from October 2005 to July 2007
* Patients referred to the CESF for possible diagnosis of a sleep disorder

Exclusion Criteria:

* incomplete data
* patients with concomitant diseases (heart disease, hormonal disease, chronic obstructive pulmonary disease and neurological patients)
* patients undergoing uvulopalatopharyngoplasty

Primary outcomes:
measure: Epworth's sleepiness scale
timeFrame: March 2007
Secondary outcomes:
measure: Polysomnography
timeFrame: May 2007
Other outcomes:
Locations:
city: Fortaleza
country: Brazil
facility: Fortaleza University - Nucleus of Integrated Medical Attention
state: Ceará
Study officials:
affiliation: Fortaleza University
name: Ingrid C Nogueira, Bachelor
role: PRINCIPAL_INVESTIGATOR
affiliation: Fortaleza University
name: Ana Cristhina O Brasil, Master
role: STUDY_DIRECTOR
affiliation: Fortaleza University
name: Priscilla O Azevedo, Bachelor
role: PRINCIPAL_INVESTIGATOR
affiliation: Fortaleza University
name: Vera Maria A Lacerda, Bachelor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00783185: Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment
Official title: Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psychotic Disorders
Marijuana Abuse
Intervention
Keywords: psychotic disorders
cannabis
intervention
Lead sponsor: University of Konstanz
Sponsor class: OTHER
First posted: 2008-10-31
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.

Detailed description: Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of schizophrenia and disorders with psychotic features
* Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria:

* Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)
* Discharge from hospital before completion of training

Primary outcomes:
measure: PANSS Positive and Negative Symptom Scale
timeFrame: post intervention, six months follow-up
Secondary outcomes:
measure: Urinstatus for cannabinoids
timeFrame: weekly during and post intervention, follow-up
Other outcomes:
Locations:
city: Konstanz
country: Germany
facility: University of Konstanz
state: Baden-Württemberg
Study officials:
affiliation: University of Konstanz
name: Hans Watzl, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04486885: European Study of Cerebral Aspergillosis Treated With Isavuconazole
Official title: European Study of Cerebral Aspergillosis Treated With Isavuconazole
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Aspergillosis
Invasive Aspergillosis
Keywords: cerebral aspergillosis
isavuconazole
Lead sponsor: Imagine Institute
Sponsor class: OTHER
First posted: 2020-07-27
Enrollment: 41
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 40 adult ou pediatric patients, suffering frome cerebral aspergillosis, diagnosed between 2017 and 2020, and treated by isavuconazole at least 7 days

Brief summary: Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile.

The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.


Eligibility criteria: Inclusion Criteria:

* Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria
* In child or adult
* Treated by isavuconazole at least 7 days
* Diagnosed between March 2017 and June 2020

Exclusion Criteria:

* Possible cerebral aspergillosis
* isavuconazole treatment for less than 7 days

Primary outcomes:
measure: Outcome of the patients : alive without CA treatment/alive under CA treatment/ deceased.
timeFrame: At baseline
Secondary outcomes:
measure: Monitoring of isavuconazole : dosage in the serum and in the cerebro-spinal-fluid
timeFrame: At baseline
measure: -Adverse events under isavuconazole and drug interactions
timeFrame: At baseline
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Necker-Enfants Malades
Study officials:
affiliation: Hôpital Necker
name: Fanny Lanternier, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05005585: Vestibular Socket Therapy With Simultaneous Implant Placement Versus Contour Augmentation With Early Implant Placement
Official title: Vestibular Socket Therapy With Simultaneous Implant Placement Versus Contour Augmentation With Early Implant Placement in Fresh Extraction Sockets : A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Loss of Teeth Due to Extraction
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-08-13
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: VST with immediate implant placement versus contour augmentation with early implant placement in fresh extraction sockets in esthetic zone.
Primary purpose: TREATMENT

Brief summary: immediate implant placement with VST technique versus early implant placement with contour augmentation in fresh extraction sockets in the esthetic zone.

Detailed description: comparing VST technique with immediate implant placement that end up with final crown after 2 months with contour augmentation with early implant placement after 4- 8 weeks of soft tissue healing , then after 3 months final crown delivery both in fresh extraction sockets in the esthetic zone .

Eligibility criteria: Inclusion Criteria:

Non-restorable maxillary teeth in the esthetic zone

Intact adjacent teeth

Adequate palatal and apical bone that allows achieving implant primary stability.

Compromised sockets type II defect (Nicolas Elian 2007)

≥18 years

Systemically healthy patients

Exclusion Criteria:

Extraction sockets with acute or chronic infection or with adjacent infected teeth

Heavy Smokers \> than 10 cigarettes daily

Cancer patients undergoing radiotherapy or chemotherapy during or within the last 6 months.

Unmotivated patients to maintain adequate oral hygiene to follow up.

Patients with physical disabilities that could affect follow up.

Primary outcomes:
measure: Implant survival
timeFrame: 12 months
Secondary outcomes:
measure: Changes in the height and thickness of the labial plate of bone
timeFrame: 12 months
measure: Changes in soft tissue height
timeFrame: 12 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dentistry Cairo university
state: Giza
city: Cairo
country: Egypt
facility: Faculty of dentistry
state: Manial
city: Cairo
country: Egypt
facility: Iman AbdelWahab Radi
Study officials:
affiliation: Professor of prosthodontics
name: Iman Radi, PHD
role: STUDY_DIRECTOR
affiliation: Private Practice
name: AbdelSalam ElAsakry, BDS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02197585: Comparison of Mesh Fixation Wit Cyanoacrylate vs Suture in Inguinal Hernia Surgery
Official title: Cyanoacrylate vs Suture for Mesh Fixation in Inguinal Hernia Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Keywords: Male patients
Age > 18 year
Primary hernia
glue
Lead sponsor: Hospital del Mar
Sponsor class: OTHER
First posted: 2014-07-22
Enrollment: 150
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare fixation with glubran2 with suture during surgery por primary inguinal hernia.

Hypothesis: Glue may induce less complications and chronic pain than suture


Eligibility criteria: Inclusion Criteria:

* Male patients
* Aged more than 18 years
* Primary inguinal hernia

Exclusion Criteria:

* Inguinoscrotal hernia

Primary outcomes:
measure: Chronic pain after two years
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital del Mar
name: JA Pereira, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06131385: Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）
Official title: Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Stroke, Acute
Lead sponsor: The Affiliated Hospital Of Southwest Medical University
Sponsor class: OTHER
First posted: 2023-11-14
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute ischemic stroke who received intravenous thrombolysis will be included in the study and no additional exclusion criteria have been set.

Brief summary: This study aims to observe the safety and effectiveness of intravenous thrombolysis for acute ischemic stroke in real-world clinical practice.

Detailed description: IVTIS is a prospective, real-world registry lasting for 22 years. A total of 3000 patients with intravenous thrombolysis will be enrolled。

Eligibility criteria: Inclusion Criteria:

* The patient was diagnosed with acute ischemic stroke and received intravenous thrombolysis.

Exclusion Criteria:

* No additional exclusion criteria.

Primary outcomes:
measure: modified Rankin Scale (mRS) score
timeFrame: 90±7 days
Secondary outcomes:
measure: Excellent functional outcome
timeFrame: 90±7 days
measure: Good functional outcome
timeFrame: 90±7 days
measure: mRS 0-3
timeFrame: 90±7 days
measure: Change of National Institutes of Health Stroke Scale (NIHSS)
timeFrame: 24 hours
measure: Change of National Institutes of Health Stroke Scale (NIHSS)
timeFrame: 7 days
measure: Symptom-to-thrombolysis time
timeFrame: 24 hours
measure: Door-to-Needle Time
timeFrame: 24 hours
measure: Incidence of clinically significant intracranial hemorrhage
timeFrame: 36 hours
measure: Incidence of any intracranial hemorrhage
timeFrame: 36 hours
measure: All-cause mortality
timeFrame: 90±7 days
measure: Complications related to intravenous thrombolysis
timeFrame: up to 7 days
Other outcomes:
Locations:
city: Luzhou
country: China
facility: Affiliated Hospital of Southwest Medical University
Study officials:
affiliation: Department of Neurology, Affiliated Hospital of Southwest Medical University, Lu
name: Zhengzhou Yuan
role: STUDY_CHAIR
References:
Clinical trial NCT02292485: PCORI-CER-1306-03385 Lung Cancer Screening Readiness Study
Official title: Promoting Informed Decisions About Lung Cancer Screening: Lung Cancer Screening Readiness Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Cancer Screening
Keywords: Lung Cancer Screening
LCS
Survey
Questionnaire
Texas Academy of Family Physicians
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Patient-Centered Outcomes Research Institute
First posted: 2014-11-17
Enrollment: 1000
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.

Brief summary: Investigators will administer a brief, anonymous survey at the Texas Academy of Family Physicians (TAFP) annual Primary Care Summit to better understand the readiness of primary care physicians in Texas to implement lung cancer screening programs in their practice settings.

Detailed description: For this project there will be up to 1000 participants. Physicians attending the annual CME event at the Texas Academy of Family Physicians event will be asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. The surveys will be administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.

Eligibility criteria: Inclusion Criteria:

1. Physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.

Exclusion Criteria:

N/A

Primary outcomes:
measure: Lung Cancer Screening Program Readiness
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Robert Volk, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04325685: The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia
Official title: The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia and Associated Microbiomes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trauma Injury
Brain Injuries
Abdominal Sepsis
Pancreatitis
Meningitis
Encephalitis
Seizures
Acute Respiratory Distress Syndrome
Lead sponsor: Northern State Medical University
Sponsor class: OTHER
First posted: 2020-03-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Oropharynx is the main source of pathogen microorganisms for the ventilator - associated pneumoniae. As known bacteriophages can eliminate different pathogen microorganisms or reduce a degree of a pathogen's colonization. The research team is considering that oropharyngeal decontamination with bacteriophages can prevent the developing of the ventilator - associated pneumoniae. There will be three groups in this investigation: placebo, antiseptic drug (Octenisept) and bacteriophage (Sexthaphag).


Eligibility criteria: Inclusion Criteria:

- invasive mechanical ventilation beyond 48 hours

Exclusion Criteria:

* hospital - acquired pneumonia
* community - acquired pneumoniae
* BMI \> 35 kg/cm2
* pregnancy
* tracheostomy
* reintubation

Primary outcomes:
measure: Incidence of ventilator-associated pneumonia (VAP)
timeFrame: Change from Baseline CPIS at 14 days
measure: Changing of oral and lung microbiomes
timeFrame: Change from Baseline Microbiology researching at 14 days
Secondary outcomes:
measure: Organ dysfunction
timeFrame: Change from Baseline Sequential Organ Function Assessment at 14 days
measure: Concentration of C - reactive protein (CRP)
timeFrame: Change from Baseline CRP at 14 days
measure: Concentration of Procalcitonin (PCT)
timeFrame: Change from Baseline PCT at 14 days
measure: Rate of Mortality
timeFrame: Change from Baseline PCT at 28 days
Other outcomes:
Locations:
city: Severodvinsk
country: Russian Federation
facility: Budgetary Healthcare Institution of Arkhangelsk Region "Severodvinsk City Clinical Emergency Hospital # 2"
state: Arkhangelsk Region
Study officials:
References:
Clinical trial NCT02050685: Comparison of Different Screening Score for Hypoxemic OSA (Obstructive Sleep Apnea) With the Results of a Polysomnography (PSG)
Official title: Comparison of Different Screening Score for Hypoxemic OSA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea, Obstructive
Lead sponsor: Astes
Sponsor class: OTHER
First posted: 2014-01-31
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adults patients for an overnight polysomnography at SLBO.

Brief summary: Comparison of different screening score for hypoxemic OSA (Obstructive Sleep Apnea) with the results of a polysomnography (PSG). The different screening score studied are: STOP-BANG, DES-OSA, P-SAP and OSA50.

Detailed description: The investigators should compare the four screening scores (STOP-BANG, DES-OSA, P-SAP and OSA50) with the results of the PSG (and in particular the number of apnea and hypopnea index and the probability of hypoxemia).

Eligibility criteria: Inclusion Criteria:

* Adults patients (\> 18 years)

Exclusion Criteria:

* None

Primary outcomes:
measure: Comparison of the DES-OSA score with previously described scores.
timeFrame: The day before the PSG (PolySomnoGraphy)
Secondary outcomes:
measure: Comparison of the four screening scores with results of the PSG.
timeFrame: The day after the polysomnography
Other outcomes:
Locations:
city: Bouge
country: Belgium
facility: Clinique Saint-Luc de Bouge
state: Namur
Study officials:
affiliation: Astes
name: Eric P DEFLANDRE, MD, FCCP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Deflandre E, Piette N, Bonhomme V, Degey S, Cambron L, Poirrier R, Brichant JF, Joris J. Comparison of clinical scores in their ability to detect hypoxemic severe OSA patients. PLoS One. 2018 May 7;13(5):e0196270. doi: 10.1371/journal.pone.0196270. eCollection 2018.